Ownership
Private
Employees
~100
Therapeutic Areas
Women's HealthOncologyCardiovascular
Stage
Commercial
Modalities
Medical devicesMicrosphere drug delivery systemMedical devices

CeloNova BioSciences General Information

Company has developed Polyzene-F nanocoating technology for medical devices, showing low thrombosis, restenosis and inflammation with rapid healing effects. Their COBRA PzF NanoCoated Coronary Stent demonstrated safety and efficacy with 1-month dual antiplatelet therapy.

Contact Information

Website
Primary Industry
[ "Biotech", "Medical Devices" ]
Corporate Office
San Antonio, Texas
United States

Drug Pipeline

COBRA PzF NanoCoated Coronary Stent
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to CeloNova BioSciences's pipeline data

Book a demo

Key Partnerships

Boston Scientific, Proximo Medical

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

CeloNova BioSciences Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view CeloNova BioSciences's complete valuation and funding history, request access ยป